AC Immune SA
ACIU
$2.39
-$0.05-2.05%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 310.44% | -99.98% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 310.44% | -99.98% | -- | -- | -- |
| Cost of Revenue | -3.90% | -13.54% | -14.28% | -11.25% | -7.07% |
| Gross Profit | 25.53% | 8.15% | 20.02% | 17.09% | 13.05% |
| SG&A Expenses | 2.90% | 9.24% | -7.41% | -11.06% | -12.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.37% | -32.51% | -16.93% | -0.74% | -7.99% |
| Total Operating Expenses | -2.87% | -10.09% | -13.36% | -11.39% | -8.38% |
| Operating Income | 20.03% | 5.47% | 18.05% | 16.08% | 13.14% |
| Income Before Tax | 18.99% | 4.60% | 12.43% | 11.01% | 7.02% |
| Income Tax Expenses | -19.12% | -18.92% | 18.69% | 64.47% | 312.12% |
| Earnings from Continuing Operations | 18.99% | 4.61% | 12.43% | 11.00% | 7.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.99% | 4.61% | 12.43% | 11.00% | 7.01% |
| EBIT | 20.03% | 5.47% | 18.05% | 16.08% | 13.14% |
| EBITDA | 20.52% | 5.53% | 18.29% | 16.20% | 13.23% |
| EPS Basic | 19.66% | 5.55% | 15.67% | 17.52% | 16.68% |
| Normalized Basic EPS | 19.68% | 5.04% | 14.81% | 16.69% | 15.86% |
| EPS Diluted | 19.66% | 5.55% | 15.67% | 17.52% | 16.68% |
| Normalized Diluted EPS | 19.68% | 5.04% | 14.81% | 16.69% | 15.86% |
| Average Basic Shares Outstanding | 1.36% | 0.94% | 3.94% | 7.81% | 11.79% |
| Average Diluted Shares Outstanding | 1.36% | 0.94% | 3.94% | 7.81% | 11.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
